Physician profile
Alex G P Reish
NPI 1760694525
$8,991.32
in general payments reported to CMS, 2019-2025
31 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 86% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,520 · 2020: $865 · 2021: $1,261 · 2022: $1,739 · 2023: $1,410 · 2024: $1,195 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,605.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,606.35 | 2021-2025 | |
| Pfizer INC. | $1,059.11 | 2019-2025 | |
| Amgen INC. | $662.05 | 2019-2022 | |
| Allergan, INC. | $523.31 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $516.39 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $509.91 | 2019-2023 | |
| Lundbeck LLC | $509.32 | 2020-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company Ltd. | $507.88 | 2022 | |
| Lilly USA, LLC | $455.32 | 2019-2024 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $344.40 | 2019-2024 | Ajovy |
| Zyla Life Sciences, INC. | $316.93 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $222.02 | 2019-2021 | |
| Medtronic, INC. | $212.68 | 2021 | |
| Merz Pharmaceuticals, LLC | $194.54 | 2021-2025 | Xeomin |
| Saluda Medical Americas, INC. | $189.28 | 2024 | Evoke |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mml US, INC. | $163.79 | 2022 | |
| Assertio Therapeutics, INC. | $154.20 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $150.97 | 2022 | |
| Abbott Laboratories | $139.90 | 2023 | Eterna |
| Merz North America, INC. | $117.88 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $105.97 | 2019-2021 | |
| Axsome Therapeutics, INC. | $93.02 | 2023-2025 | Symbravo, Auvelity |
| Vertex Pharmaceuticals Incorporated | $60.24 | 2024-2025 | |
| Arbor Pharmaceuticals, INC. | $55.06 | 2019-2022 | |
| Bioventus LLC | $24.43 | 2019 | |
| Avanir Pharmaceuticals, INC. | $21.66 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.84 | 2024 | Horizant |
| Mdd US Operations, LLC | $16.98 | 2019 | |
| Scilex Pharmaceuticals INC. | $13.92 | 2019 | |
| Promius Pharma LLC | $13.88 | 2019 | |
| Bausch Health US, LLC | $12.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Reish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.